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Abstract
Background: Specific peptide ligands to cell surface receptors have been extensively used in tumor research and
clinical applications. Phage display technology is a powerful tool for the isolation of cell-specific peptide ligands. To
screen and identify novel markers for renal cell carcinoma, we evaluated a peptide that had been identified by
phage display technology.
Methods: A renal carcinoma cell line A498 and a normal renal cell line HK-2 were used to carry out subtractive
screening in vitro with a phage display peptide library. After three rounds of panning, there was an obvious
enrichment for the phages specifically binding to the A498 cells, and the output/input ratio of phages increased
about 100 fold. A group of peptides capable of binding specifically to the renal carcinoma cells were obtained,
and the affinity of these peptides to the targeting cells and tissues was studied.
Results: Through a cell-based ELISA, immunocytochemical staining, immunohistochemical staining, and
immunofluorescence, the Phage ZT-2 and synthetic peptide ZT-2 were shown to specifically bind to the tumor cell
surfaces of A498 and incision specimens, but not to normal renal tissue samples.
Conclusion: A peptide ZT-2, which binds specifically to the renal carcinoma cell line A498 was selected from
phage display peptide libraries. Therefore, it provides a potential tool for early diagnosis of renal carcinoma or
targeted drug delivery in chemotherapy.
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Introduction
Renal cell carcinoma (RCC) accounts for 3% of all adult
malignancies and is the most lethal urological cancer. It
accounted more than 57, 000 new cases and 13, 000 can-
cer-related deaths in the United States in 2009[1]. In
China around 23, 000 new patients with RCC are diag-
nosed each year, and the incidence is increasing rapidly
due to the aging population [2]. Approximately 60% of
patients have clinically localized disease at presentation,
with the majority undergoing curative nephrectomy.
However, metastatic disease recurs in a third of these
patients. The patients with metastatic RCC have a poor
prognosis with a median survival time of 1 to 2 years [3].
Detection of RCC in early stages helps increase the life
expectancy of the patient [4]. Two diagnosis methods, his-
topathology and image procedures (computed tomography
scan, ultrasonography, or magnetic resonance imaging)
provide increase the early detection of the RCC. Histo-
pathologically, although several promising biomarkers
such as Carbonic anhydrase IX, B7-H1 and P53 for RCC
have been under investigation, none currently have been
validated or are in routine use [5,6]. Therefore, some novel
molecular markers must be screened and identified for
improving early diagnosis and prognosis of RCC.
Phage display is a molecular diversity technology that
allows the presentation of large peptide and protein
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any medium, provided the original work is properly cited.libraries on the surface of filamentous phage. Phage dis-
play libraries permit the selection of peptides and pro-
teins, including antibodies, with high affinity and
specificity for all targets. An important distinctive mark
of this technology is the direct link that exists between
the experimental phenotype and its encapsulated geno-
type. Phage display technology is a powerful tool for the
selection of cell-specific peptide ligands at present [7].
Some laboratories have applied this technology to isolate
peptide ligands with good affinity and specificity for a
variety of cell types. The specific ligands isolated from
phage libraries can be used in diagnostic probe, thera-
peutic target validation, and drug design and vaccine
development [8-10].
In the present study, we identified a specific novel
peptide that bound to the cell surface of renal carci-
noma cell line A498 generated in this laboratory by
using in vitro phage-displayed random peptide libraries.
Our results demonstrate that this biopanning strategy
can be used to identify tumor-specific targeting peptides.
One of our selected peptides, ZT-2 was most effective in
targeting cells and tissues, indicating its potential for use
in early diagnosis and targeted therapy of RCC.
Materials
Renal carcinoma line A498 and a normal renal cell line
HK-2 were obtained from Medical Academy of China
(Beijing, PR China). Fetal calf serum (FCS) and Dulbecco’s
modified eagle’s medium (DMEM) were purchased from
G i b c o( I n v i t r o g e n ,C a r l s b a d ,U S A ) .P h a g eD N As e q u e n -
cing was performed by Shanghai Sangon Corp (Shanghai,
PR China). Peptide ZT-2 (QQPPMHLMSYAG) and a
nonspecific control peptide (EAFSILQWPFAH) were
synthesized and labeled with fluorescein isothiocyanate
(FITC) by Shanghai Bioengineering Ltd. Mass analysis of
the peptides was confirmed by a matrix-assisted laser des-
orption/ionization time-of-flight mass spectrometry, and
all peptides were > 90% pure as determined by reverse-
phase HPLC. Peptide stock solutions were prepared in
PBS (pH 7.4). Horseradish peroxidase-conjugated sheep
anti-rabbit antibody and rabbit anti-M13 bacteriophage
antibody were purchased from Pharmacia (Peapack, NJ,
USA). Trizol reagents were purchased from Gibco BRL
(Gaithersburg, MD, USA) and the reverse transcriptase
polymerase chain reaction (RT-PCR) system kits were pur-
chased from Promega (Madison, WI, USA).
T h eP h . D . - 1 2p h a g ed i s p l a yp e p t i d el i b r a r yk i t( N e w
England Biolabs, Beverly, MA, USA) was used to screen
specific peptides binding to A498 cells. The phage dis-
play library contains random peptides constructed at the
N terminus of the minor coat protein (cpIII) of the M13
phage. The titer of the library is 2.3 × 10
13 pfu (plaque-
forming units). The library contains a mixture of 3.1 ×
10
9 individual clones, representing the entire obtainable
repertoire of 12-mer peptide sequences that express ran-
dom twelve-amino-acid sequences. Extensively sequen-
cing the naive library has revealed a wide diversity of
sequences with no obvious positional biases.
The E. coli host strain ER2738 (a robust F
+ strain with
a rapid growth rate) (New England Biolabs) was used
for M13 phage propagation. The A498 and HK-2 cells
were cultured in DMEM supplemented with penicillin,
streptomycin, and 10% fetal bovine serum. Cells were
harvested when subconfluent, and the total number of
cells was counted using a hemocytometer.
In Vitro Panning
A498 cells were taken as the target cells, and HK-2 as
the absorber cells for a whole-cell subtractive screening
from a phage display 12-peptide library. Cells were cul-
t u r e di nD M E Mw i t h1 0 %F C Sa t3 7 ° Ci nah u m i d i f i e d
atmosphere containing 5% CO2. HK-2 cells were washed
with PBS and kept in serum-free DMEM for 1 h before
blocking with 3 mL blocking buffer (BF, PBS + 5% BSA)
for 10 min at 37°C. Approximately 2 × 10
11 pfu phages
were added and mixed gently with the blocked HK-2 for
1 h at 37°C. Cells were then pelleted by centrifuging at
1000 rpm (80 g)f o r5m i n .H K - 2a n dp h a g e sb o u n dt o
these cells were removed by centrifugation. Those
phages in the supernatant were incubated with the BF-
blocked A498 cells for 1 h at 37°C before cells were pel-
leted again. After that, the pelleted cells were washed
twice with 0.1% TBST (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 0.1% Tween-20) to remove unbound phage
particles. A498 cells and bound phages were both incu-
bated with the E. coli host strain ER2738. Then, the
phages were rescued by infection with bacteria while the
cells died. The phage titer was subsequently evaluated
by a blue plaque-forming assay on agar plates containing
tetracycline. Finally, a portion of purified phage prepara-
tion was used as the input phage for the next round of
in vitro selection.
For each round of selection, more than 1.5 × 10
11 pfu
of collected phages were used. The panning intensity
was increased by prolonging the phage incubation per-
iod with HK-2 for 1.25 h or 1.5 h, shortening the phage
incubation with A498 for 45 min and 30 min in the sec-
ond and third rounds individually, and increasing wash-
ing with TBST for 4 times and 6 times in the second
and third round individually.
Sequence Analysis of Selected Phages and Peptide
Synthesis
After three rounds of in vitro panning, 60 blue plaques
were randomly selected and their sequences were ana-
lyzed with an ABI Automatic DNA Analyzer (Shanghai
Sangon Corp). A primer used for sequencing was 5’-
C C CT C AT A GT T AG C GT A AC G - 3 ’ (-96 gIII
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play peptide library kit). Homologous analysis and mul-
tiple sequence alignment were done using the BLAST
and Clustal W programs to determine the groups of
related peptides.
Cell-Based ELISA with Phage
A498 and HK-2 were cultured in DMEM with 10% FCS
at 37°C in a humidified atmosphere containing 5% CO2,
and the cells were seeded into 96-well plates (1 × 10
5
cells/well) overnight. Cells were then fixed on 96-well
plates by 4% paraformaldehyde for 15 min at room tem-
perature until cells were attached to the plates. Tripli-
cate determinations were done at each data point.
Selectivity was determined using a formula as follows
[11]: Selectivity = ODM13 -O D C1/ODS2 -O D C2. Here,
ODM13 and OD C1 represent the OD values from the
selected phages and control phages binding to A498
cells, respectively. OD S2 and ODC2 represent the OD
values from the selected phage and control phage bind-
ing to the control (HK-2 cell line), respectively.
Immunocytochemical Staining and Immunohistochemical
Staining of Phage M13
Before staining with phage M13 [12], the cells in the dif-
ferent groups (A498 and HK-2) were cultured on cover-
slips and fixed with acetone at 4°C for 20 min. Then,
about 1 × 10
11 pfu of phage M13 diluted in PBS were
added onto the coverslips and incubated at 4°C over-
night. Coverslips were then washed for five times with
TBST. The coverslips were blocked by H2O2 (3% in
PBS) at room temperature for 510 min. After being
washed by PBS for 5 min at 37°C, the coverslips were
incubated with normal sheep serum for 20 min at 37°C.
Subsequently, the coverslips were incubated overnight at
4°C with a mouse anti-M13 phage antibody at a dilution
of 1:5000. The next day, the coverslips were rinsed for
three times (10 min for each rinse) in PBS and incu-
bated with a secondary antibody for 1 h at room tem-
perature. Afterward, the coverslips were rinsed three
times (5 min for each rinse) in PBS. The bound anti-
body was visualized using DAB. The coverslips were
rinsed for three times (5 min for each rinse) using run-
ning tap water before staining by hematoxylin and
eosin. Finally, the coverslips were rinsed for 10 min with
running tap water before dehydration and mounting.
Frozen sections of human renal tissues with and with-
out tumors were also prepared. The steps of immuno-
histochemical staining were similar to those for
immunocytochemical staining described above. Instead
of the selected phage clone M13, PBS and a nonspecific
control phage with same titers were used for negative
controls. The study protocol was reviewed and approved
by the Institutional Review Board and Ethic Committee
of the First Affiliated Hospital of Sun Yat-Sen University
(NO.2011-137), and oral or written informed consent
was obtained from all subjects prior to enrollment in
the study.
Peptide Synthesis and Labeling
The ZT-2 peptide (QQPPMHLMSYAG) translated from
the selected M13 phage DNA sequence and nonspecific
control peptide (EAFSILQWPFAH) were synthesized
and purified by Shanghai Bioengineering Ltd. Fluores-
cein isothiocyanate (FITC)-conjugated peptides were
also produced by the same company.
Peptide Competitive Inhibition Assay for Characterization
of Specific Phage Clones
The in vitro blue-plaque forming assay was performed
to observe the competitive inhibition effect of ZT-2 pep-
tide with its phage counterparts (M13). A498 cells were
cultured in a 12-well plate overnight and then preincu-
bated with blocking buffer to block nonspecific binding
at 4°C for 30 min. The synthetic peptide (0, 0.0001,
0.001, 0.01, 0.1, 1 or 10 μM) was diluted in PBS and
incubated with cells at 4°C for 1 h, and then incubated
with 1 × 10
11 pfu of phage M13 at 4°C for 1 h. The
bound phages were recovered and titered in ER2738 cul-
ture. The phages binding to A498 cells were evaluated
by blue plaque-forming assay, and the rate of inhibition
was calculated by the following formula: Rate of inhibi-
tion = (number of blue plaques in A498 incubated with
PBS - number of blue plaques in A498 with ZT-2 pep-
tide)/number of blue plaques in A498 incubated with
PBS × 100%. Nonspecific control phages (a synthetic
peptide corresponding to an unrelated phage picked
randomly from the original phage peptide library) were
used as negative controls.
Immunofluorescence Microscopy and Image Analysis
Immunofluorescence microscopy was used to study the
affinity of synthetic peptide (ZT-2) binding to A498 and
renal carcinoma. A498 and HK-2 were digested with
0.25% trypsin and plated on coverslips overnight. Cells
were washed three times with PBS and fixed with acet-
one at 4°C for 20 min before analysis. ZT-2 peptide
labeled with FITC was incubated with cells. PBS and
control peptides labeled with FITC were used as nega-
tive controls. After being washed for three times with
PBS, the slips were observed using a fluorescence
microscope.
Results
Specific Enrichment of A498 Cell-Bound Phages
Phages specifically bound to human A498 cells were
identified through three rounds of in vitro panning. In
each round, the bound phages were rescued and
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while the unbound phages were removed by washing
with TBST. After the third round of the in vitro selec-
tion, the number of phages recovered from A498 cells
increased 100-fold (Table 1). However, the number of
phages recovered from HK-2 control cells decreased.
The output/input ratio of phages recovered after each
round of the panning was used to determine the phage
recovery efficiency. These results indicated an obvious
enrichment of phages specifically binding to A498 cells.
Verification of In Vitro Specific Binding by Cell-Based
ELISA
A cellular ELISA was used to identify the affinities for
the twenty selected phages binding to A498. To assess
selectivity, the affinities of each phage binding to A498
cells and to the control HK-2w e r ec o m p a r e d .T h e s e
phage clones bound more effectively to A498 cells com-
pared with PBS and HK-2 control groups. Furthermore,
the ZT-2 clone appeared to bind most effectively to
A498 cells than the other clones (Figure 1). Therefore,
we further analyzed the phage M13 and its displaying
peptide ZT-2.
Affinity of the Phage M13 to A498 Cells and Renal
carcinoma Tissues
To confirm the binding ability of the selected phage
toward target A498 cells, the phage clone M13 (clone
ZT-2) was isolated, amplified and purified for immuno-
chemical assay. The HK-2 cell line, composed of human
nontumor renal tissues, was included as a negative con-
trol. The interaction of the M13 phage and target cells
(A498) was evaluated by immunocytochemical staining.
A498 cells bound by the phage M13 were stained brown
in contrast to the HK-2 cells. Negative results were also
obtained when A498 cells bound with unrelated phage
clone. However, A498 cells bound with phage clone ZT-
2 were stained brown distinctively, demonstrating that
ZT-2 was able to bind specifically to A498 cells (Figure
2). Subsequently, immunohistochemical stain was per-
formed to observe the specific binding of the phage
clone ZT-2 toward human renal carcinoma tissues. The
cells in A498 tumor tissue sections when bound with
phage clone ZT-2 were stained green fluorescence dis-
tinctively. When A498 tumor tissue sections bound by
unrelated phage clone or the normal renal tissue sec-
tions when bound with phage clone ZT-2 showed nega-
tive staining. It is thus clear that the phage clone ZT-2
was able to bind specifically to A498 cells (Figure 3).
Competitive Inhibition Assay
A peptide-competitive inhibition assay was performed to
discover whether the synthetic peptide ZT-2 and the
corresponding phage clone competed for the same
Table 1 Enrichment of phages for each round of
selection from phage displayed peptide library
Rounds Selected Phage
(input) (cpu)
Eluted Phage
(output) (cpu)
Ratio
(output/input)
1 1.5 × 10
11 1.5 × 10
3 1×1 0
-8
21 0
12 10
5 10
-7
31 0
12 10
6 10
-6
Figure 1 Evaluation by cell-ELISA of the binding selectivity of
twenty phage clones. The selectivity values of five higher phage
clone (ZT-2, ZT-4, ZT-8, ZT-9, and ZT-16), calculated by the formula
mentioned in the text, were 3.15, 2.90, 2.95, 2.80, and 3.05,
respectively. Therefore, clone ZT-2 appeared to bind more
effectively than the other clones.
Figure 2 Immunocytochemical staining of A498 and control
cells when bound with phage ZT-2. Cell-bound phages were
detected using anti-M13 phage monoclonal antibody, secondary
antibody, and ABC complex. The cells were stained with
diaminobenzidine (DAB). (A) shows control cell (B) shows
immunocytochemical staining of A498 cells when bound with
phages without exogenous sequences (wild-type phage) (C) shows
immunocytochemical staining of A498 cells when bound with
unrelated phage (D) shows immunocytochemical staining of A498
cells when bound with phage ZT-2. Amplification × 200.
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incubated with A498 cells, phage ZT-2 binding to A498
cells decreased in a dose-dependent manner. When the
peptide ZT-2 concentrations increased, the titer of
phages recovered from A498 cells was decreased and
the inhibition was increased gradually. When the con-
centrations of peptide ZT-2 increased above 5 μM, the
inhibition reached a flat phase. The control peptide
(EAFSILQWPFAH) had no effect on the binding of the
phage ZT-2 to A498 cells (Figure 4).
Discussion
Targeting specific ligand binding on specific tumor anti-
gens is an efficient way to increase the selectivity of
therapeutic targets in clinical oncology and helpful for
the early detection and therapy of RCC. Tumor cells
often display certain cell surface antigens such as
tumor-associated antigens or tumor-specific antigens in
high quantity, which are different from the antigens on
normal tissues. To develop more biomarkers for the
diagnosis of RCC, we used peptide phage display tech-
nology to identify potential molecular biomarkers of
A498 carcinoma cells. After panning for three rounds,
20 clones were selected for further characterization.
First, a cell-based ELISA assay was used to confirm the
specific binding of the phage clones to A498 cells in
vitro. ZT-2 was the best candidate phage clone with the
highest specificity. Second, immunocytochemical and
immunohistochemical staining were performed to con-
firm the selectivity of the phage ZT-2 to bind to A498
cells. Third, the results of the competitive inhibitory
assays suggest that the peptide displayed by the phage
M13-ZT-2, not other parts of this phage, can bind to
the renal carcinoma cell surface. Under the same condi-
tions, the normal renal cell line HK-2 did not show sig-
nificant fluorescence when stained with ZT-2 peptide-
FITC, which confirmed the targeting of ZT-2 to be
A498 cells.
Monoclonal antibodies have become the most rapidly
expanding class of drugs for treating kidney cancer, but
poor tumor penetration, bone marrow toxicity and high
immunogenicity of these antibodies have been limited in
clinical applications [13,14]. Compared with monoclonal
antibodies, peptide ligands, which have the advantages
of rapid tissue penetration, faster blood clearance, easy
incorporation into certain delivery vectors and low
immunogenicity are being pursued as targeting moieties
for the selective delivery of radionuclides cytokines, che-
mical drugs, or therapeutic g e n e st ot u m o r s[ 1 5 ] .T h i s
effect may open up diagnostic procedures and therapeu-
tic options for the patient. Identification of the cancer
Figure 3 Immunohistochemical staining of renal carcinoma and nontumorous renal tissue sections when bound with ZT-2 peptide-
fluorescein isothiocyanate. To investigate if the free ZT-2 peptide maintained its binding affinity to renal carcinoma cells, we made a synthetic
peptide ZT-2 (QQPPMHLMSYAG) labeled with fluorescein isothiocyanate. (A) Immunohistochemical staining of renal carcinoma tissues when
bound with phage ZT-2-FITC. The specific binding sites on tumor cells fluoresced green (B) Immunohistochemical staining of nontumorous renal
tissues when bound with phage ZT-2 (C) a negative control section stained with random peptide-fluorescein isothiocyanate in renal carcinoma
tissues. Magnification × 200.
Figure 4 Competitive inhibition of binding of the phage ZT-2
to A498 cells by the synthetic peptide ZT-2 QQPPMHLMSYAG.
The average inhibition rates at different concentrations of the
peptide are shown. When the concentration of the peptide ZT-2
reached more than 0.001 μM, a significant inhibition occurred.
Tu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:105
http://www.jeccr.com/content/30/1/105
Page 5 of 6cell receptors that binds the ZT-2 peptide would allow
further improvement of the peptide for potential clinical
use.
These preliminary experiments provide evidence that
the ZT-2 peptide may be specific to A498 and therefore
it would be useful for diagnosis of renal carcinoma or
delivery of an antitumor therapeutic agent. Studies are
continuing to identify the cellular receptors responsible
for peptide binding and to apply the peptide to clinically
relevant samples.
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